JP2024509910A - Mage-a4ペプチド-mhc抗原結合タンパク質 - Google Patents
Mage-a4ペプチド-mhc抗原結合タンパク質 Download PDFInfo
- Publication number
- JP2024509910A JP2024509910A JP2023555203A JP2023555203A JP2024509910A JP 2024509910 A JP2024509910 A JP 2024509910A JP 2023555203 A JP2023555203 A JP 2023555203A JP 2023555203 A JP2023555203 A JP 2023555203A JP 2024509910 A JP2024509910 A JP 2024509910A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- domain
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158691P | 2021-03-09 | 2021-03-09 | |
| US63/158,691 | 2021-03-09 | ||
| US202163172864P | 2021-04-09 | 2021-04-09 | |
| US63/172,864 | 2021-04-09 | ||
| PCT/IB2022/052119 WO2022190009A1 (en) | 2021-03-09 | 2022-03-09 | Mage-a4 peptide-mhc antigen binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509910A true JP2024509910A (ja) | 2024-03-05 |
| JP2024509910A5 JP2024509910A5 (cg-RX-API-DMAC10.html) | 2025-03-17 |
Family
ID=80787264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555203A Pending JP2024509910A (ja) | 2021-03-09 | 2022-03-09 | Mage-a4ペプチド-mhc抗原結合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11912771B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4304726A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024509910A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230169944A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022233285A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3210289A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023010541A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022190009A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| EP4304726A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Mage-a4 peptide-mhc antigen binding proteins |
| CA3240046A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
| EP4587046A1 (en) | 2022-09-14 | 2025-07-23 | CDR-Life AG | Mage-a4 peptide dual t cell engagers |
| CN119490592B (zh) * | 2023-08-14 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗κ型轻链抗体及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018225732A1 (ja) * | 2017-06-05 | 2018-12-13 | 国立大学法人三重大学 | Mage-a4由来ペプチドを認識する抗原結合性タンパク質 |
| JP2019513383A (ja) * | 2016-04-08 | 2019-05-30 | アダプティミューン・リミテッド | T細胞受容体 |
| WO2020193767A1 (en) * | 2019-03-27 | 2020-10-01 | Medigene Immunotherapies Gmbh | Mage a4 t cell receptors |
| WO2021016585A1 (en) * | 2019-07-24 | 2021-01-28 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| JP2022535479A (ja) * | 2019-12-18 | 2022-08-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Hla-a2/mage-a4に結合する抗体 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199231B1 (en) | 1991-05-23 | 2007-04-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| AU5992999A (en) | 1998-10-02 | 2000-04-26 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| AU2003264009A1 (en) | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
| CN100415765C (zh) | 2003-08-07 | 2008-09-03 | 宜康公司 | 兔单克隆抗体的人源化方法 |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| NZ579594A (en) | 2007-03-12 | 2012-03-30 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
| NZ601583A (en) | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| NZ581468A (en) | 2007-06-25 | 2012-09-28 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| CN101688200B (zh) | 2007-06-25 | 2012-08-08 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 单链抗体的基于序列的改造和优化 |
| PL2307455T3 (pl) | 2008-06-25 | 2017-09-29 | Esbatech, An Alcon Biomedical Research Unit Llc | Optymalizacja rozpuszczalności cząsteczek immunowiążących |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| CA2771575A1 (en) * | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| WO2013048243A1 (en) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| HK1245171A1 (zh) | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| KR20190065189A (ko) | 2016-04-08 | 2019-06-11 | 어댑티뮨 리미티드 | T 세포 수용체 |
| IL308831A (en) | 2016-04-08 | 2024-01-01 | Immunocore Ltd | T cell receptors |
| HRP20251020T1 (hr) | 2016-05-20 | 2025-10-24 | Harpoon Therapeutics, Inc. | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 |
| US11590098B2 (en) * | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| EP3601536A4 (en) | 2017-03-20 | 2021-01-13 | Genocea Biosciences, Inc. | TREATMENT PROCEDURES |
| MX2020001879A (es) | 2017-08-18 | 2020-07-29 | Gritstone Oncology Inc | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. |
| AU2018395397A1 (en) | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| JP7326764B2 (ja) | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
| CA3102254A1 (en) | 2018-06-04 | 2019-12-12 | Apo-T B.V. | Methods and means for attracting immune effector cells to tumor cells |
| CN108866098A (zh) | 2018-07-27 | 2018-11-23 | 北京安斯晨睿生物科技有限公司 | 携带mage-a4突变抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| MX2021015946A (es) | 2019-06-18 | 2022-04-18 | Regeneron Pharma | Receptores de linfocitos t de mage-a4 y métodos de uso de estos. |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN110333352A (zh) | 2019-08-07 | 2019-10-15 | 基因科技(上海)股份有限公司 | 肿瘤相关自身抗体及肿瘤标志物联合检测试剂盒 |
| CN115803340A (zh) | 2020-04-24 | 2023-03-14 | 纪念斯隆凯特琳癌症中心 | 抗cd3抗体及其用途 |
| CN116096754A (zh) | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| EP4149631A1 (en) | 2020-05-13 | 2023-03-22 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| US20230190803A1 (en) | 2020-05-13 | 2023-06-22 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| CN118878693A (zh) | 2020-11-23 | 2024-11-01 | 康诺亚生物医药科技(成都)有限公司 | 一种双特异性抗体及其用途 |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| EP4304726A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Mage-a4 peptide-mhc antigen binding proteins |
| JP2024516308A (ja) | 2021-05-04 | 2024-04-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Mage-a4特異性を有するキメラ抗原受容体及びその使用 |
| WO2022262678A1 (zh) | 2021-06-15 | 2022-12-22 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
| US20240327543A1 (en) | 2021-08-02 | 2024-10-03 | Shenghe (China) Biopharmaceutical Co., Ltd. | Multispecific antigen-binding protein and use thereof |
| CN117730103A (zh) | 2021-08-02 | 2024-03-19 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
| KR20240040097A (ko) | 2021-08-04 | 2024-03-27 | 에이비프로 코퍼레이션 | Cd3 표적화 항체 및 이의 용도 |
| CA3231006A1 (en) | 2021-09-17 | 2023-03-23 | Adimab, Llc | Anti-cd3 antibodies |
-
2022
- 2022-03-09 EP EP22711322.2A patent/EP4304726A1/en active Pending
- 2022-03-09 JP JP2023555203A patent/JP2024509910A/ja active Pending
- 2022-03-09 MX MX2023010541A patent/MX2023010541A/es unknown
- 2022-03-09 US US17/690,526 patent/US11912771B2/en active Active
- 2022-03-09 WO PCT/IB2022/052119 patent/WO2022190009A1/en not_active Ceased
- 2022-03-09 AU AU2022233285A patent/AU2022233285A1/en active Pending
- 2022-03-09 KR KR1020237031175A patent/KR20230169944A/ko active Pending
- 2022-03-09 CA CA3210289A patent/CA3210289A1/en active Pending
-
2024
- 2024-01-04 US US18/404,536 patent/US20240279344A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513383A (ja) * | 2016-04-08 | 2019-05-30 | アダプティミューン・リミテッド | T細胞受容体 |
| WO2018225732A1 (ja) * | 2017-06-05 | 2018-12-13 | 国立大学法人三重大学 | Mage-a4由来ペプチドを認識する抗原結合性タンパク質 |
| WO2020193767A1 (en) * | 2019-03-27 | 2020-10-01 | Medigene Immunotherapies Gmbh | Mage a4 t cell receptors |
| WO2021016585A1 (en) * | 2019-07-24 | 2021-01-28 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| JP2022535479A (ja) * | 2019-12-18 | 2022-08-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Hla-a2/mage-a4に結合する抗体 |
Non-Patent Citations (2)
| Title |
|---|
| AKAHORI Y.: "J-1036. Development of TCR-like scFv CAR that recognizes MAGE-A4230-239/HLA-A*02:01 complex.", CANCER SCIENCE, vol. 109, Suppl 1, JPN7026001056, September 2018 (2018-09-01), pages 102, ISSN: 0005818102 * |
| SANDERSON JP. ET AL.: "Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell", ONCOIMMUNOLOGY, vol. 9, 1, JPN7026001057, 24 November 2019 (2019-11-24), pages 1682381, ISSN: 0005818103 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022190009A1 (en) | 2022-09-15 |
| US11912771B2 (en) | 2024-02-27 |
| EP4304726A1 (en) | 2024-01-17 |
| US20220380472A1 (en) | 2022-12-01 |
| US20240279344A1 (en) | 2024-08-22 |
| KR20230169944A (ko) | 2023-12-18 |
| CA3210289A1 (en) | 2022-09-15 |
| MX2023010541A (es) | 2023-11-24 |
| AU2022233285A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912771B2 (en) | MAGE-A4 peptide-MHC antigen binding proteins | |
| US12509520B2 (en) | Anti-CD3 and anti-CD123 bispecific antibody and use thereof | |
| US12435444B2 (en) | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same | |
| US20250144141A1 (en) | Mage-a4 peptide dual t cell engagers | |
| TW202340240A (zh) | 多特異性抗體及其藥物用途 | |
| WO2022117032A1 (zh) | 抗cd22的纳米抗体及其用途 | |
| CA3226441A1 (en) | B7-h3 antibody and use thereof | |
| KR20250143344A (ko) | 항-cdh6 항체 및 이의 용도 | |
| US20250002586A1 (en) | Dual mhc-targeting t cell engager | |
| WO2023186100A1 (zh) | 抗ror1的抗体及其用途 | |
| US20250333514A1 (en) | Antigen binding proteins targeting an hla-restricted prame peptide | |
| CN116234559A (zh) | 抗cd22单结构域抗体和治疗性构建体 | |
| CN117751146A (zh) | Mage-a4肽-mhc抗原结合蛋白 | |
| WO2025210181A1 (en) | Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide | |
| WO2026013159A1 (en) | Antibodies binding to constant domains of gamma delta t-cell receptors | |
| WO2025146128A1 (zh) | 抗liv-1的抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250307 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250307 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260306 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260616 |